Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Klages, C. Mayer, K. Lahl, C. Loddenkemper, M. Teng, oong Ngiow, M. Smyth, A. Hamann, J. Huehn, T. Sparwasser (2010)
Cancer esearch oenvironment and Immunology ctive Depletion of Foxp 3 + Regulatory T Cells roves Effective Therapeutic Vaccination R inst Established Melanoma
le Teng, S. Ngiow, B. Scheidt, N. McLaughlin, parwasser, M. Smyth (2010)
Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth
E. Pasquier, M. Kavallaris, N. André (2010)
Metronomic chemotherapy: new rationale for new directionsNature Reviews Clinical Oncology, 7
E. Barber, Emese Zsíros, J. Lurain, A. Rademaker, J. Schink, N. Neubauer (2013)
The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancerJournal of Gynecologic Oncology, 24
R. Kaneno, G. Shurin, Felipe Kaneno, H. Naiditch, Jianhua Luo, M. Shurin (2011)
Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cellsCellular Oncology, 34
Shi-feng Kan, S. Hazama, K. Maeda, Y. Inoue, S. Homma, S. Koido, M. Okamoto, M. Oka (2012)
Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro.Anticancer research, 32 12
Nelson Paolo, S. Tuve, Shaoheng Ni, K. Hellström, I. Hellström, A. Lieber (2006)
Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.Cancer research, 66 2
T. Browder, C. Butterfield, B. Kräling, B. Shi, B. Marshall, M. O’Reilly, J. Folkman (2000)
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.Cancer research, 60 7
H. Zhong, B. Han, I. Tourkova, A. Lokshin, A. Rosenbloom, M. Shurin, G. Shurin (2007)
Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer GrowthClinical Cancer Research, 13
K. Lien, Soley Georgsdottir, Lavarnan Sivanathan, Kelvin Chan, U. Emmenegger (2013)
Low-dose metronomic chemotherapy: a systematic literature analysis.European journal of cancer, 49 16
L. Apetoh, F. Ghiringhelli, A. Tesnière, A. Tesnière, A. Tesnière, M. Obeid, M. Obeid, M. Obeid, Carla Ortiz, Carla Ortiz, Carla Ortiz, A. Criollo, A. Criollo, A. Criollo, G. Mignot, G. Mignot, G. Mignot, M. Maiuri, E. Ullrich, E. Ullrich, E. Ullrich, P. Saulnier, Huan Yang, S. Amigorena, B. Ryffel, F. Barrat, P. Saftig, F. Lévi, F. Lévi, R. Lidereau, C. Noguès, J. Mira, A. Chompret, V. Joulin, F. Clavel-Chapelon, J. Bourhis, F. André, S. Delaloge, T. Tursz, G. Kroemer, G. Kroemer, G. Kroemer, L. Zitvogel (2007)
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 13
S. Tu, Huanyu Jin, Jin Shi, Li Zhu, Ya Suo, Gang Lu, A. Liu, T. Wang, Chung Yang (2011)
Curcumin Induces the Differentiation of Myeloid-Derived Suppressor Cells and Inhibits Their Interaction with Cancer Cells and Related Tumor GrowthCancer Prevention Research, 5
M. Lutsiak, R. Semnani, R. Pascalis, S. Kashmiri, J. Schlom, H. Sabzevari (2005)
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.Blood, 105 7
L. Galluzzi, L. Senovilla, L. Zitvogel, G. Kroemer (2012)
The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 11
Hiroaki Tanaka, H. Matsushima, N. Mizumoto, A. Takashima (2009)
Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells.Cancer research, 69 17
G. Shurin, Camille Ouellette, M. Shurin (2012)
Regulatory dendritic cells in the tumor immunoenvironmentCancer Immunology, Immunotherapy, 61
E. Suzuki, V. Kapoor, A. Jassar, L. Kaiser, S. Albelda (2005)
Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune ActivityClinical Cancer Research, 11
S. Shiao, Ganesan Ap, Ganesan Ap, H. Rugo, L. Coussens (2011)
Immune microenvironments in solid tumors: new targets for therapy.Genes & development, 25 24
A. Sevko, V. Kremer, C. Falk, L. Umansky, M. Shurin, G. Shurin, V. Umansky (2012)
Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal miceJournal of Immunotoxicology, 9
A. Sevko, Moshe Sade-Feldman, Julia Kanterman, T. Michels, C. Falk, L. Umansky, Marcel Ramacher, Masashi Kato, D. Schadendorf, M. Baniyash, V. Umansky (2013)
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.The Journal of investigative dermatology, 133 6
F. Ghiringhelli, L. Apetoh, A. Tesnière, L. Aymeric, Yuting Ma, Carla Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, J. Perfettini, F. Schlemmer, E. Tasdemir, M. Uhl, P. Génin, A. Civas, B. Ryffel, J. Kanellopoulos, J. Tschopp, F. André, R. Lidereau, N. McLaughlin, N. Haynes, M. Smyth, G. Kroemer, L. Zitvogel (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumorsNature Medicine, 15
W. Fridman, J. Galon, M. Dieu-Nosjean, I. Cremer, S. Fisson, D. Damotte, F. Pagès, E. Tartour, C. Sautès-Fridman (2011)
Immune infiltration in human cancer: prognostic significance and disease control.Current topics in microbiology and immunology, 344
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
K Klages, CT Mayer, K Lahl, C Loddenkemper, MW Teng, SF Ngiow, MJ Smyth, A Hamann, J Huehn, T Sparwasser (2010)
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanomaCancer Res, 70
H. Naiditch, M. Shurin, G. Shurin (2011)
Targeting myeloid regulatory cells in cancer by chemotherapeutic agentsImmunologic Research, 50
J. Vincent, G. Mignot, Fanny Chalmin, S. Ladoire, M. Bruchard, A. Chevriaux, F. Martin, L. Apetoh, C. Rébé, F. Ghiringhelli (2010)
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.Cancer research, 70 8
M. Bruchard, G. Mignot, V. Derangère, Fanny Chalmin, A. Chevriaux, F. Végran, W. Boireau, B. Simon, B. Ryffel, J. Connat, J. Kanellopoulos, F. Martin, C. Rébé, L. Apetoh, F. Ghiringhelli (2012)
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growthNature Medicine, 19
Yang Ma, G. Shurin, Dmitriy Gutkin, M. Shurin (2012)
Tumor associated regulatory dendritic cells.Seminars in cancer biology, 22 4
Lorna Rettig, S. Seidenberg, I. Parvanova, P. Samaras, A. Knuth, S. Pascolo (2011)
Gemcitabine depletes regulatory T‐cells in human and mice and enhances triggering of vaccine‐specific cytotoxic T‐cellsInternational Journal of Cancer, 129
M. Shurin (2013)
Dual role of immunomodulation by anticancer chemotherapyNature Medicine, 19
A. Sevko, T. Michels, Melissa Vrohlings, L. Umansky, P. Beckhove, Masashi Kato, G. Shurin, M. Shurin, V. Umansky (2013)
Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma ModelThe Journal of Immunology, 190
G. Shurin, I. Tourkova, M. Shurin (2008)
Low-dose Chemotherapeutic Agents Regulate Small Rho GTPase Activity in Dendritic CellsJournal of Immunotherapy, 31
G. Shurin, Yang Ma, M. Shurin (2013)
Immunosuppressive Mechanisms of Regulatory Dendritic Cells in CancerCancer Microenvironment, 6
E. Ustinova, G. Shurin, Dmitriy Gutkin, M. Shurin (2013)
The Role of TLR4 in the Paclitaxel Effects on Neuronal Growth In VitroPLoS ONE, 8
F. Ademuyiwa, K. Miller (2008)
Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer.Clinical breast cancer, 8 Suppl 4
M. Todaro, V. Orlando, G. Cicero, N. Caccamo, S. Meraviglia, G. Stassi, F. Dieli (2013)
Chemotherapy Sensitizes Colon Cancer Initiating Cells to Vγ9Vδ2 T Cell-Mediated CytotoxicityPLoS ONE, 8
K. Hida, Kosuke Akiyama, N. Ohga, N. Maishi, Y. Hida (2013)
Tumour endothelial cells acquire drug resistance in a tumour microenvironment.Journal of biochemistry, 153 3
S. Geary, C. Lemke, D. Lubaroff, A. Salem (2013)
The Combination of a Low-Dose Chemotherapeutic Agent, 5-Fluorouracil, and an Adenoviral Tumor Vaccine Has a Synergistic Benefit on Survival in a Tumor Model SystemPLoS ONE, 8
M. Shurin, H. Naiditch, Dmitriy Gutkin, V. Umansky, G. Shurin (2012)
ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents.Current medicinal chemistry, 19 12
R. Spíšek, M. Dhodapkar (2007)
Towards a Better Way to Die with Chemotherapy: Role of Heat Shock Protein Exposure on Dying Tumor CellsCell Cycle, 6
G. Rabinovich, D. Gabrilovich, E. Sotomayor (2007)
Immunosuppressive strategies that are mediated by tumor cells.Annual review of immunology, 25
J. Fucikova, P. Králíková, A. Fialová, T. Brtnicky, L. Rob, J. Bartunkova, R. Spíšek (2011)
Human tumor cells killed by anthracyclines induce a tumor-specific immune response.Cancer research, 71 14
A. Facciabene, Gregory Motz, G. Coukos (2012)
T-regulatory cells: key players in tumor immune escape and angiogenesis.Cancer research, 72 9
G. Shurin, I. Tourkova, R. Kaneno, M. Shurin (2009)
Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism1The Journal of Immunology, 183
Y. Eralp, Xiaoyan Wang, Jian-ping Wang, Maureen Maughan, J. Polo, L. Lachman (2004)
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma modelBreast Cancer Research, 6
Abhishek Garg, D. Nowis, J. Gołąb, P. Vandenabeele, D. Krysko, P. Agostinis (2010)
Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation.Biochimica et biophysica acta, 1805 1
J. Fontenot, M. Gavin, A. Rudensky (2003)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cellsNature Immunology, 4
P. Serafini, Kristen Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, I. Borrello (2006)
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionThe Journal of Experimental Medicine, 203
D. Adeegbe, H. Nishikawa (2013)
Natural and Induced T Regulatory Cells in CancerFrontiers in Immunology, 4
J. Galon, A. Costes, F. Sánchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoué, P. Bruneval, P. Cugnenc, Z. Trajanoski, W. Fridman, F. Pagès (2006)
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 313
T. Michels, G. Shurin, H. Naiditch, A. Sevko, V. Umansky, M. Shurin (2012)
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent mannerJournal of Immunotoxicology, 9
M. Loeffler, J. Krüger, R. Reisfeld (2005)
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.Cancer research, 65 12
Sudesh Pawaria, R. Binder (2011)
CD91-dependent programming of T-helper cell responses following heat shock protein immunization.Nature communications, 2
C. Banissi, F. Ghiringhelli, Lin Chen, A. Carpentier (2009)
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma modelCancer Immunology, Immunotherapy, 58
S. Sierro, A. Donda, R. Perret, P. Guillaume, H. Yagita, F. Lévy, P. Romero (2011)
Combination of lentivector immunization and low‐dose chemotherapy or PD‐1/PD‐L1 blocking primes self‐reactive T cells and induces anti‐tumor immunityEuropean Journal of Immunology, 41
M. Obeid, A. Tesnière, T. Panaretakis, R. Tufi, N. Joza, P. Endert, F. Ghiringhelli, L. Apetoh, N. Chaput, C. Flament, E. Ullrich, S. Botton, L. Zitvogel, G. Kroemer (2007)
Ecto‐calreticulin in immunogenic chemotherapyImmunological Reviews, 220
Y. Khaled, B. Ammori, E. Elkord (2013)
Myeloid‐derived suppressor cells in cancer: recent progress and prospectsImmunology and Cell Biology, 91
C. Mackall (2000)
T‐Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A ReviewSTEM CELLS, 18
M. Tongu, N. Harashima, Hiroyuki Monma, T. Inao, Takaya Yamada, H. Kawauchi, M. Harada (2013)
Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivoCancer Immunology, Immunotherapy, 62
M Todaro, V Orlando, G Cicero, N Caccamo, S Meraviglia, G Stassi, F Dieli (2013)
Chemotherapy sensitizes colon cancer initiating cells to Vgamma9Vdelta2 T cell-mediated cytotoxicityPLoS ONE, 8
A. Soriani, A. Zingoni, C. Cerboni, M. Iannitto, M. Ricciardi, Valentina Gialleonardo, M. Cippitelli, C. Fionda, M. Petrucci, A. Guarini, R. Foà, A. Santoni (2009)
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.Blood, 113 15
Wei Li, D. Fan, Ming Yang, Yan Yan, Ruizan Shi, Junping Cheng, Zhen-zhen Li, Mengnan Zhang, Jianxiang Wang, D. Xiong (2013)
Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody.Human gene therapy, 24 8
R. Kaneno, G. Shurin, I. Tourkova, M. Shurin (2009)
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrationsJournal of Translational Medicine, 7
K. Hida, N. Ohga, Kosuke Akiyama, N. Maishi, Y. Hida (2013)
Heterogeneity of tumor endothelial cellsCancer Science, 104
R. Siegel, D. Naishadham, A. Jemal (2013)
Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 63
Abhishek Garg, S. Martin, J. Gołąb, P. Agostinis (2013)
Danger signalling during cancer cell death: origins, plasticity and regulationCell Death and Differentiation, 21
F. Ghiringhelli, N. Larmonier, E. Schmitt, A. Parcellier, Dominique Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, F. Martin (2004)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 34
G. Klement, P. Bőhlen, R. Kerbel (2000)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.The Journal of clinical investigation, 105 8
Lin Zhang, J. Conejo-Garcia, D. Katsaros, P. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. Liebman, S. Rubin, G. Coukos (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.The New England journal of medicine, 348 3
M. Obeid, A. Tesnière, F. Ghiringhelli, G. Fimia, L. Apetoh, J. Perfettini, M. Castedo, G. Mignot, T. Panaretakis, N. Casares, D. Métivier, N. Larochette, P. Endert, F. Ciccosanti, M. Piacentini, L. Zitvogel, G. Kroemer (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell deathNature Medicine, 13
H. Inoue, Kenzaburo Tani (2013)
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatmentsCell Death and Differentiation, 21
P. Antony, C. Piccirillo, A. Akpinarli, S. Finkelstein, P. Speiss, D. Surman, D. Palmer, C. Chan, C. Klebanoff, W. Overwijk, S. Rosenberg, N. Restifo (2005)
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory CellsThe Journal of Immunology, 174
Traditionally, anticancer chemotherapy has been generally considered to be strongly immunosuppressive. However, increasing evidence suggests that certain chemotherapeutic agents rely on the induction of antitumor immune responses, in both experimental animal models and patients with cancer. Many of these chemotherapeutic agents exert immunogenic effects via the induction and release of immunostimulatory “danger” signals from dying cancerous cells when used in low doses. New data suggests that several common chemotherapeutic agents may also display direct stimulating effects on immune cells even when applied in ultra-low concentrations (chemoimmunomodulation). Importantly, it is becoming clear that both immune effector cells and immune regulatory cells can be targeted by various chemotherapeutic agents to produce favorable antitumor immune responses. Therefore, utilizing cancer drugs to enhance host antitumor immunity should be considered a feasible therapeutic approach; and recent characterization of the immunomodulatory mechanisms of anticancer chemotherapy using both new and traditional cytotoxic agents suggests that combinations of these approaches with “classical” immunomodulatory agents could lead to a viable new therapeutic paradigm for the treatment of cancer.
Cancer Microenvironment – Springer Journals
Published: Nov 29, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.